Intellia Therapeutics, Inc.
NASDAQ:NTLABiotechnology
+$0.02 today
- Market cap
- $1.37B
- Beta
- 1.81
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$3.33
Volume 7.23M
Average 6.11M
NTLA Operating Expenses
Total costs of running the business that are not directly tied to producing goods or services sold.
Intellia Therapeutics, Inc.NASDAQ: NTLA
Operating Expenses · Q1 FY2026 · quarter ended Mar 2026
Operating expenses declines year over year
Q1 FY2026 operating expenses of $113.38M fell 17.5% year over year, behind the -10.9% change in trailing-twelve-month operating expenses. Sequentially, it fell 2.0% from the prior quarter. Over 3 fiscal years it compounded at -0.7% a year.
Context
- Operating expenses amounted to 728.1% of revenue in FY2025, down 277.2 pp from a year earlier.
- Operating expenses increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -17.5% toward the trailing-twelve-month pace of -10.9%.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Expenses history
USD · from the income statement
- Latest · FY2025
- 492.74M USD
- Year-over-year change
- -15.3%
- 4-year CAGR
- +13.8%
| Period | Period end | Operating Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 492.74M | -15.3% |
| FY2024 | 2024-12-31 | 581.86M | +7.2% |
| FY2023 | 2023-12-31 | 542.59M | +7.9% |
| FY2022 | 2022-12-31 | 502.71M | +71.0% |
| FY2021 | 2021-12-31 | 294.01M | — |
Operating Expenses vs competitors
How NTLA compares with its peers on the latest reported figures
- NTLA's LTM Mar 2026 operating expenses of $319.11M is the 3rd highest of the 10 companies compared; the peer median is $204.75M.
- Its year-over-year change of -10.9% is the 8th highest of 10, against a peer median of +10.6%.
- Operating expenses amounts to 482.8% of revenue for NTLA, versus a peer median of 342.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $534.06M | +5.5% | +78.7% | 342.3% | |
| LTM Sep 2026 | $389.17M | +13.2% | -15.6% | 1546.0% | |
| LTM Mar 2026 | $319.11M | -10.9% | -0.7% | 482.8% | |
| LTM Mar 2026 | $235.17M | +10.6% | -13.2% | — | |
| LTM Mar 2026 | $213.72M | -20.2% | -1.0% | — | |
| LTM Mar 2026 | $204.75M | +13.6% | -6.4% | 1131.6% | |
| LTM Mar 2026 | $178.28M | +5.9% | +11.3% | 223.5% | |
| LTM Mar 2026 | $140.97M | +26.8% | +7.2% | 1258.3% | |
| LTM Mar 2026 | $117.37M | -46.1% | -16.4% | 303.3% | |
| LTM Jun 2026 | $116.27M | +12.5% | +4.6% | 135.6% | |
| Peer median (excluding NTLA) | $204.75M | +10.6% | -1.0% | 342.3% | |
Competitors are the stored peer set for NTLA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 33.05M | 52.12M | 36.28M | 57.88M | 67.67M |
| Cost of Revenue | 6.89M | 7.57M | 8.98M | 10.29M | 15.92M |
| Gross Profit | 26.16M | 44.55M | 27.3M | 47.59M | 51.75M |
| Gross Margin | 79.2% | 85.5% | 75.3% | 82.2% | 76.5% |
| Research & Development | 229.81M | 419.98M | 435.07M | 466.31M | 388.86M |
| Selling, General & Admin | 71.1M | 90.31M | 116.5M | 125.83M | 119.8M |
| Operating Expenses | 294.01M | 502.71M | 542.59M | 581.86M | 492.74M |
| Depreciation & Amortization | 6.89M | 7.57M | 8.98M | 10.29M | 15.92M |
| EBITDA | (261M) | (466.61M) | (472.22M) | (508.74M) | (396.77M) |
| EBITDA Margin | -789.6% | -895.3% | -1301.8% | -879.0% | -586.3% |
| Operating Income | (267.85M) | (458.16M) | (515.29M) | (534.26M) | (440.99M) |
| Operating Margin | -810.4% | -879.0% | -1420.5% | -923.1% | -651.7% |
| Interest Income | 1.28M | 8.54M | 49.83M | 47.81M | 29.2M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (42K) | (16.02M) | 34.1M | 15.24M | 28.3M |
| Income Before Tax | (267.89M) | (474.19M) | (481.19M) | (519.02M) | (412.69M) |
| Pre-Tax Margin | -810.5% | -909.8% | -1326.5% | -896.8% | -609.9% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (267.89M) | (474.19M) | (481.19M) | (519.02M) | (412.69M) |
| Net Margin | -810.5% | -909.8% | -1326.5% | -896.8% | -609.9% |
| EPS (Basic) | (3.78) | (6.16) | (5.42) | (5.25) | (3.81) |
| EPS (Diluted) | (3.78) | (6.16) | (5.42) | (5.25) | (3.81) |
| Weighted Avg Shares | 70.89M | 76.97M | 88.77M | 98.85M | 108.38M |
| Weighted Avg Shares (Diluted) | 70.89M | 76.97M | 88.77M | 98.85M | 108.38M |
Intellia Therapeutics, Inc.
NASDAQ:NTLA
Intrinsic Alpha fair value
Locked
Current Price
$9.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.